Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma

Maximilian Erlmeier; Marie Mikuteit; Stefanie Zschäbitz; Michael Autenrieth; Wilko Weichert; Arndt Hartmann; Sandra Steffens; Franziska Erlmeier

doi:10.1186/s12894-023-01263-0

Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma

BMC Urol. 2023 May 11;23(1):90. doi: 10.1186/s12894-023-01263-0.

Authors

Maximilian Erlmeier¹, Marie Mikuteit², Stefanie Zschäbitz³, Michael Autenrieth⁴, Wilko Weichert⁵, Arndt Hartmann⁶, Sandra Steffens^#^{7

8}, Franziska Erlmeier^#⁶

Affiliations

¹ Department of Urology, München Klinik Bogenhausen, Munich, Germany.
² Department for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany. Mikuteit.marie@mh-hannover.de.
³ Dept. of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
⁴ Department of Urology, Technical University of Munich, Klinikum Rechts der Isar, München, Germany.
⁵ Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
⁶ Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
⁷ Department for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
⁸ Department of Urology, University Hospital Münster, Münster, Germany.

^# Contributed equally.

Abstract

Background: The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC).

Methods: Patients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry.

Results: 81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF^- compared to HGF⁺ tumors (95.0% versus 90.9%; p = 0.410).

Conclusions: In chRCC HGF expression is not associated with parameters of aggressiveness or survival.

Keywords: Chromophobe histology; HGF; Renal Cell Carcinoma; Survival.

MeSH terms

Biomarkers, Tumor / metabolism
Carcinoma, Renal Cell* / surgery
Hepatocyte Growth Factor
Humans
Kidney Neoplasms* / surgery
Prognosis
Retrospective Studies

Substances

Hepatocyte Growth Factor
Biomarkers, Tumor